Research programme: atypical antipsychotics - FAES FarmaAlternative Names: F-93013-GD
Latest Information Update: 16 Jul 2016
At a glance
- Originator FAES Farma
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Psychotic disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Psychotic-disorders in Spain
- 23 Mar 2009 Preclinical trials in Psychotic disorders in Spain (unspecified route)